ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.488
-0.73%
Brent Oil
83.76
0.00%
Bitcoin
66,797.22
-0.21%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lyra Therapeutics Inc (LYRA)

  7. Lyra Therapeutics Inc (LYRA) Noticias

LYRA Lyra Therapeutics Inc

0.3876
0.02 (5.44%)
17 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lyra Therapeutics Inc LYRA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.02 5.44% 0.3876 23:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.3707 0.356 0.4185 0.383 0.3676
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202406:59GLOBELyra Therapeutics Reports Topline Results from Phase 3..
30/4/202415:04GLOBELyra Therapeutics Reports First Quarter 2024 Financial..
26/4/202415:51GLOBELyra Therapeutics Announces Inducement Grants Under Nasdaq..
21/3/202415:01GLOBELyra Therapeutics Reports Fourth Quarter and Full Year 2023..
01/3/202415:01GLOBELyra Therapeutics Announces Inducement Grant Under Nasdaq..
15/2/202408:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202419:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202417:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202415:34EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:13EDGAR2Form 8-K - Current report
28/12/202305:40EDGAR2Form 8-K - Current report
18/12/202315:16EDGAR2Form 8-K - Current report
16/11/202316:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/11/202316:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202315:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202315:09EDGAR2Form 8-K - Current report
07/11/202315:01GLOBELyra Therapeutics Reports Third Quarter 2023 Financial..
07/11/202306:00GLOBELyra Therapeutics to Participate in Upcoming Investor..
16/10/202306:00GLOBELyra Therapeutics Announces Appointment of Ronan O’Brien as..
12/9/202315:01EDGAR2Form 8-K - Current report
12/9/202306:00GLOBELyra Therapeutics Announces Positive Topline Results from..
06/9/202307:00GLOBELyra Therapeutics to Participate in Upcoming Investor..
01/9/202315:03EDGAR2Form 8-K - Current report
01/9/202315:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/8/202306:00GLOBELyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I..
25/8/202315:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/8/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:03EDGAR2Form 8-K - Current report
08/8/202315:01GLOBELyra Therapeutics Reports Second Quarter 2023 Financial..
14/7/202315:06EDGAR2Form 8-K - Current report
13/7/202306:30GLOBELyra Therapeutics to Present at William Blair Virtual..
12/7/202317:36EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
07/7/202315:44EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/7/202320:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202320:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202315:06EDGAR2Form S-3 - Registration statement under Securities Act of..
02/6/202315:01GLOBELyra Therapeutics Announces Inducement Grant Under Nasdaq..
02/6/202306:30GLOBELyra Therapeutics to Present at Jefferies Healthcare..
01/6/202306:29GLOBELyra Therapeutics Announces Closing of $50.0 Million Private..
26/5/202306:57GLOBELyra Therapeutics Announces $50.0 Million Private Placement

Su Consulta Reciente

NASDAQ
LYRA
Lyra Therapeutics
ASX
PEKOD
Peak Rare Earths
NYSE
EVC
Entravision Communications
LSE
HVO
Hvivo
NYSE
GWW
WW Grainger
NYSE
HPS
John Hancock Preferred I...
NYSE
NNY
Nuveen New York Municipa...
LSE
0VIO
Stars
NASDAQ
NSTC
Ness
NYSE
NMD
ASX
PMYDA
Pacifico Minerals
AMEX
PYR
Pyr Energy
NASDAQ
ARTC
NYSE
PBT
Permian Basin Royalty
ASX
KYK
Kyckr
LSE
0KBI
Knorr Bremse
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados